Checkpoint Therapeutics to Present at H.C. Wainwright Conference
Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a prominent name in the realm of clinical-stage immunotherapy and targeted oncology, is thrilled to announce its participation in the esteemed H.C. Wainwright 26th Annual Global Investment Conference. During this event, James Oliviero, the company's President and Chief Executive Officer, will provide a comprehensive overview of Checkpoint's mission and its innovative approaches to treating solid tumor cancers.
Presentation Details
The conference is scheduled for an upcoming Tuesday, with Checkpoint’s presentation set to begin at 10:00 a.m. ET. Attendees will have the opportunity to participate in both in-person and virtual one-on-one meetings, allowing for direct engagement with Checkpoint's leadership. This is a fantastic chance for investors to gain insights into the company's strategic plans and product advancements.
How to Access the Webcast
Those interested can easily access a webcast of the presentation on Checkpoint’s News & Events page, located in the Investors section of their official website. The webcast will be available for about 30 days following the presentation, ensuring that even those unable to attend live can still catch up on the information shared.
About Checkpoint Therapeutics
Based in Waltham, Massachusetts, Checkpoint is dedicated to the acquisition, development, and commercialization of innovative therapies aimed at treating complex solid tumors. The company is particularly excited about its leading antibody product candidate, cosibelimab, which is a potentially differentiated anti-PD-L1 antibody licensed from the prestigious Dana-Farber Cancer Institute. This candidate is currently being evaluated for its effectiveness as a new treatment option for patients with certain recurrent or metastatic cancers, especially those with metastatic and locally advanced cutaneous squamous cell carcinoma (cSCC).
Advancements in Drug Development
In addition, Checkpoint is actively assessing olafertinib, its flagship small-molecule targeted anti-cancer agent recognized as a third-generation epidermal growth factor receptor (EGFR) inhibitor. This drug is under investigation for its potential as an innovative treatment for patients with EGFR mutation-positive non-small cell lung cancer. These initiatives underscore Checkpoint's steadfast dedication to improving patient outcomes through targeted therapies.
Contact Information for the Company
For further inquiries, you can reach out to the company’s Media Relations:
Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com
Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
arr@lifesciadvisors.com
Frequently Asked Questions
What is Checkpoint Therapeutics known for?
Checkpoint Therapeutics specializes in clinical-stage immunotherapy and targeted oncology, focusing on innovative treatments for solid tumors.
Who is presenting at the H.C. Wainwright conference?
James Oliviero, the President and CEO of Checkpoint Therapeutics, will be presenting an overview of the company.
When is the H.C. Wainwright conference?
The conference is happening on an upcoming Tuesday, with Checkpoint’s presentation scheduled for 10:00 a.m. ET.
How can I access the presentation webcast?
The webcast will be available on the Investors section of Checkpoint’s website for 30 days following the conference.
What innovative drugs is Checkpoint developing?
Checkpoint is currently evaluating cosibelimab and olafertinib as potential treatments for specific cancers, highlighting its commitment to advancing oncology care.
